Batran, S. a., Haag, G. M., Belle, S., Gaiser, T., & Hofheinz, R. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. The lancet, 393(10184), . https://doi.org/10.1016/S0140-6736(18)32557-1
Chicago-Zitierstil (17. Ausg.)Batran, Salah-Eddin al-, Georg Martin Haag, Sebastian Belle, Timo Gaiser, und Ralf-Dieter Hofheinz. "Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial." The Lancet 393, no. 10184 (2019). https://doi.org/10.1016/S0140-6736(18)32557-1.
MLA-Zitierstil (9. Ausg.)Batran, Salah-Eddin al-, et al. "Perioperative Chemotherapy with Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel Versus Fluorouracil or Capecitabine Plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial." The Lancet, vol. 393, no. 10184, 2019, https://doi.org/10.1016/S0140-6736(18)32557-1.